Skip to content

Trifluridine

Nucleoside Analog Antiviral — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Also known as: 5-Trifluorothymidine, trifluorothymidine

OfpFDA approvedPMDA approvedOrphan designationATC L01BC59ATC S01AD02

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Trifluridine is an ofp drug in the Nucleoside Analog Antiviral class catalogued in DrugCentral. It was first approved by the FDA in 1980. Its mechanism of action is classified as Nucleic Acid Synthesis Inhibitors. DrugCentral lists 2 molecular targets, including UL23 and tmk. Recorded indications include Herpes simplex keratitis, Herpes simplex keratoconjunctivitis, Malignant tumor of colon and Malignant tumor of stomach.

  • Approval status: ofp (first approved 1980 by the FDA).
  • Drug class: Nucleoside Analog Antiviral; Nucleoside Metabolic Inhibitor.
  • Mechanism of action: Nucleic Acid Synthesis Inhibitors.
  • Molecular targets: UL23 and tmk (2 listed in DrugCentral).
  • Indications: Herpes simplex keratitis, Herpes simplex keratoconjunctivitis, Malignant tumor of colon and Malignant tumor of stomach.
  • ATC code: L01BC59 (Pyrimidine analogues).
  • Molecular formula: C10H11F3N2O5; molecular weight 296.20 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (4)

  • Herpes simplex keratitis
  • Herpes simplex keratoconjunctivitis
  • Malignant tumor of colon
  • Malignant tumor of stomach

Mechanism & targets

Mechanism of action (MoA)Nucleic Acid Synthesis Inhibitors
Established pharmacologic classNucleoside Analog Antiviral; Nucleoside Metabolic Inhibitor

Molecular targets (2)

TargetGeneActionActivity
Thymidine kinaseUL23unknownIC50 5.70
Thymidylate kinasetmkunknownKi 4.01

Regulatory approvals (2)

DateAgencyMarketed asApplicantOrphan
2014-03-24PMDA—Taiho Pharmaceutical Co., Ltd.Yes
1980-04-10FDA—MONARCH PHARMS

ATC classification

ATC codeTherapeutic hierarchy
L01BC59ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › ANTIMETABOLITES › Pyrimidine analogues
S01AD02SENSORY ORGANS › OPHTHALMOLOGICALS › ANTIINFECTIVES › Antivirals

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Therapy partial responder75.2
Colorectal cancer metastatic62.0
Palmar-plantar erythrodysaesthesia syndrome53.5
Drug resistance47.5
Neutropenia44.3

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Trifluridine is on its molecule page.

Molecular formulaC10H11F3N2O5
Molecular weight296.20 g/mol
CAS number70-00-8
InChIKeyVSQQQLOSPVPRAZ-RRKCRQDMSA-N
PubChem CID6256
OC[C@H]1O[C@H](C[C@@H]1O)N1C=C(C(=O)NC1=O)C(F)(F)F

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Trifluridine used for?

DrugCentral lists the following indications for Trifluridine: Herpes simplex keratitis, Herpes simplex keratoconjunctivitis, Malignant tumor of colon and Malignant tumor of stomach.

How does Trifluridine work?

Trifluridine is classified as Nucleic Acid Synthesis Inhibitors; its molecular targets in DrugCentral include UL23 and tmk.

When was Trifluridine first approved?

Trifluridine was first approved by the FDA in 1980.

What drug class does Trifluridine belong to?

Trifluridine is in the Nucleoside Analog Antiviral class.

What is the chemical formula of Trifluridine?

Trifluridine has the molecular formula C10H11F3N2O5 and a molecular weight of 296.20 g/mol.

Browse: all drugs starting with T · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

StatusOFP
First approval1980-04-10
AgencyFDA
Targets2
Indications4
FormulaC10H11F3N2O5
DrugCentral ID2743
Interactive profile